CAR-T B-ALL Global Market Forecast

  • ID: 4375351
  • Drug Pipelines
  • Region: Global
  • 130 Pages
  • iOnco-analytics
1 of 4
Commercial Assessment of New CAR-T Therapies in Relapsed/Refractory B-acute Lymphoblastic Leukaemia

FEATURED COMPANIES

  • Celgene Corporation
  • Cellectis
  • Juno Therapeutics Inc
  • Kite Pharma
  • Novartis
  • Pfizer
  • MORE

This report consists of a detailed Executive presentation (~130 slides) and MS-Excel workbook forecasting the commercial potential ($ 000s) of novel CAR-T therapies (per competitor) in both pediatric and adult r/r B-ALL(new cases) across 9 major Western markets to 2030. A patient-based flow methodology has been devised where three possible intervention scenarios for CAR-T introduction are visualized so that the optimum product positioning can be assessed. In addition, an up-todate review of B-ALL disease background, epidemiology, current and future treatments is presented along with a comprehensive review of the CAR-T landscape. Pricing and cost effectiveness considerations are also discussed. All assumptions are clearly provided.

B-ALL Acute Lymphoblastic Leukaemia (ALL) is a hematologic malignancy characterised by the proliferation and accumulation of lymphoid progenitor cells (lymphoblasts) or lymphocytes in the bone marrow, blood or in various extramedullary sites. ALL, which mainly affects the <20 yrs age group represents about 0.4% of all new cancer cases in the US with around 6500 new cases per year and ~1400 deaths (SEER, Cancer Stat Facts). Rates for ALL have been rising ~0.6% each year for the last 10 years although the 5-year survival rate shows an increasing trend.

Despite a plethora of treatment strategies and a relatively high cure rate in children (60-90%), the prognosis of those individuals with relapsing/refractory disease (r/r) is still poor. In adults, long term survival (5 year rates) are often below 10%. No current standard approach exists. CAR-T or Chimeric Antigen Receptor T cells are a promising new treatment intervention for r/r B-ALL with companies such as Novartis, Pfizer (Cellectis), Medimmune, Juno Therapeutics, and Kite Pharma involved in clinical studies. Recently, Novartis has received a FDA priority review for CTL019 (tisagenlecleucel-T) upon BLA filing for pediatric and young adult patients for r/r B-cell ALL.

*** Please allow up to 48 hours for this product to be dispatched ***

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Celgene Corporation
  • Cellectis
  • Juno Therapeutics Inc
  • Kite Pharma
  • Novartis
  • Pfizer
  • MORE
  • Executive summary
  • CAR-T treatment for r/r B-ALL – commercial model: key outputs
  • CAR-T cell therapy: projected ALL revenue forecast per scenario ($000s) (0-19yrs) to 2030 (Global)
  • CAR-T cell therapy: projected ALL revenue forecast per scenario ($000s) (0-19yrs) to 2030 (Europe)
  • CAR-T cell therapy: projected ALL revenue forecast per scenario ($000s) (0-19yrs) to 2030 (US)
  • CAR-T cell therapy: projected ALL revenue forecast per scenario ($000s) (19-65yrs) to 2030 (Global)
  • CAR-T cell therapy: projected ALL revenue forecast per scenario ($000s) (19-65yrs) to 2030 (Europe)
  • CAR-T cell therapy: projected ALL revenue forecast per scenario ($000s) (19-65yrs) to 2030 (US)
  • CTL019: projected ALL revenue forecast per scenario ($000s) (0-19yrs) to 2030 (Global)
  • CTL019: projected ALL revenue forecast per scenario ($000s) (19-65yrs) to 2030 (Global)
  • CAR-T cell therapy: revenues per competitor, 2025 snapshot (US & M5EU)
  • CAR-T cell therapy: projected ALL patient numbers (0-19yrs) to 2030 (Global)
  • CAR-T cell therapy: projected ALL patient numbers (19-65yrs) to 2030 (Global)
  • CAR-T cell therapy: projected ALL revenue forecast - price sensitivity analysis
  • B-ALL: Disease background and epidemiology
  • Leukaemia: Background
  • Acute Lymphoblastic Leukaemia: Background
  • Lymphocytes and the development of ALL
  • Lymphocyte development and ALL
  • Molecular genetics of ALL
  • Molecular genetics of ALL: common mutations [7 slides]
  • Molecular genetics of B cell ALL: Chromosomal abnormalities in children and adults with B-cell ALL and their relative frequencies
  • Epidemiology: overall ALL statistics in the US
  • 2016 ALL incidence vs other common cancer types in the US
  • Age related distribution of ALL in the US
  • Childhood ALL statistics in the US
  • Childhood ALL statistics and genetic risk factors [2 slides]
  • ALL deaths in the US with distribution by age
  • ALL distribution by race, ethnicity and sex in the US
  • [2 slides]
  • ALL new cases and deaths in the US
  • Five-year survival rate of ALL in the US
  • Epidemiology: overall ALL statistics in the UK
  • Incidence of ALL in the UK by age
  • Incidence of ALL by UK country and sex
  • ALL incidence rate trends in the UK over time, by age and sex
  • ALL incidence and deprivation in England 2006-2010
  • New leukaemia cases and deaths in the UK (2014) (all subtypes*)
  • New leukaemia cases and deaths in the US (2016) (all subtypes*)
  • ALL incidence comparison in UK, France, Germany, Italy and Spain
  • ALL mortality comparison in UK, France, Germany, Italy and Spain
  • ALL prevalence comparison in UK, France, Germany, Italy and Spain
  • Clinical presentation and diagnosis of ALL
  • Diagnosis of ALL
  • Methods of classification of ALL
  • ALL classification subtypes
  • Factors affecting the prognosis of ALL
  • Factors affecting the prognosis of ALL (cont..)
  • Current cure rates of ALL
  • Treatment of ALL: Chemotherapy phases and regimens [2 slides]
  • Treatment of ALL: following chemotherapy [2 slides]
  • ALL treatment summary
  • Treatment of ALL: the expression of CD antigens and targeted therapies [3 slides]
  • The development of monoclonal antibodies in ALL treatment [4 slides]
  • Tyrosine Kinase inhibitors in ALL treatment and their application
  • Treatment of T cell ALL
  • Treatment of relapsed/refractory (r/r) ALL [2 slides]
  • The unmet need in ALL treatment – adult
  • The unmet need in ALL treatment – pediatric
  • The unmet need in ALL treatment – outlook
  • Novel treatments for r/r B-ALL: CAR-T cells
  • Chimeric Antigen Receptors T-cells (CAR-T)
  • Cancer Immunotherapy
  • Adoptive T cell therapy - T cells
  • Antigen selection for a CAR-T approach
  • CAR-T cell therapy - Potential issues and challenges
  • Steps in the manufacture of a CAR-T cell therapy
  • Chimeric Antigen Receptor T cells (CAR-T) - Review of Key Successful Clinical Trials
  • CAR-T cell therapy - successful clinical trials for CD19-CAR-T targeting acute lymphoblastic leukaemia [3 slides]
  • Chimeric Antigen Receptors (CAR) - Current R&D pipeline
  • CAR-T Therapy - pipeline analysis methodology [2 slides]
  • CAR-T Therapy: pipeline analysis results
  • Current pipeline analysis: industry sponsored CAR-T studies for ALL
  • Current pipeline analysis: industry sponsored CAR-T studies for Leukaemia
  • In depth review of key industry sponsored programmes for ALL
  • Cellular Biomedicine Group Ltd: C-CAR011 [2 slides]
  • Juno Therapeutics Inc, Celgene Corporation: JCAR017 [3 slides]
  • Kite Pharma: KTE-C19
  • Novartis: CTL019
  • Novartis: CD19 CAR-T Long Term Follow Up/BLA filing
  • Servier, Cellectis, Pfizer: UCART19 [4 slides]
  • Cellectis: additional UCARTS
  • CAR-T treatment for r/r B-ALL: modelling commercial potential
  • Modelling rationale: CAR-T therapy
  • CAR-T cell therapy: Target product profiles (TPPs) [2 slides]
  • Modelling approach: methodology
  • Modelling approach: markets modelled in this analysis
  • B-ALL model development: Age group 0-19 yrs [2 slides]
  • Patient flow: potential CAR-T treatment scenarios (0-19 yrs)
  • B-ALL model development: Age group 19-65 yrs [2 slides]
  • Patient flow: potential CAR-T treatment scenarios (19-65 yrs)
  • CAR-T cell therapy: potential pricing policies [2 slides]
  • Pricing CAR-T therapies: comparable analysis
  • CAR-T cell therapy: pricing analogues used (LO, BASE, HI)
  • Key CAR-T clinical pipeline summary
  • Potential CAR-T launch sequence
  • Competitor market share assumptions/rationale
  • Model caveats and limitations
  • Model validations
  • Bibliography
  • About us
  • Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Celgene Corporation
  • Cellectis
  • Cellular Biomedicine Group Ltd
  • Juno Therapeutics Inc
  • Kite Pharma
  • Novartis
  • Pfizer
  • Servier
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll